Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDT-M001 in resected NSCLC
NCT07096882Phase 1Recruiting
- Sponsor
- Cytocraft Biopharmaceutical
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SDT-M001 in non-small cell lung cancer (NSCLC), sponsored by Cytocraft Biopharmaceutical. Primary endpoints: Safety profile of SDT-M001 injection at 24 months, Tolerability of SDT-M001 injection at 28 days and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
SDT-M001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07096882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096882.